These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 25634013)

  • 1. Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism.
    Devabhakthuni S; Yoon CH; Pincus KJ
    J Pharm Pract; 2016 Aug; 29(4):392-405. PubMed ID: 25634013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-specific Oral Anticoagulants in the Emergency Department.
    Peacock WF; Levy PD; Gonzalez MG; Than M
    J Emerg Med; 2016 Feb; 50(2):246-57. PubMed ID: 26614713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
    Shaw J; de Wit C; Le Gal G; Carrier M
    J Thromb Haemost; 2017 May; 15(5):925-930. PubMed ID: 28296069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
    Akwaa F; Spyropoulos AC
    Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment.
    Mahan CE
    J Thromb Thrombolysis; 2015 Apr; 39(3):295-303. PubMed ID: 25605686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral anticoagulants in the management of venous thromboembolism.
    Makaryus JN; Halperin JL; Lau JF
    Nat Rev Cardiol; 2013 Jul; 10(7):397-409. PubMed ID: 23689703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oral anticoagulants for venous thromboembolism: focus on factor Xa and thrombin inhibitors.
    Becattini C; Lignani A; Agnelli G
    Curr Drug Discov Technol; 2012 Jun; 9(2):119-28. PubMed ID: 21838660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding complications of targeted oral anticoagulants: what is the risk?
    Levine M; Goldstein JN
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):504-9. PubMed ID: 25696901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM; Finks SW
    Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
    Hirschl M; Kundi M
    Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anticoagulants in the management of venous thromboembolism in women.
    Piovella F; Irina Iosub D
    Thromb Res; 2015 Feb; 135 Suppl 1():S5-7. PubMed ID: 25903537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban for prevention and treatment of venous thromboembolism.
    Chan NC; Weitz JI
    Future Cardiol; 2019 Mar; 15(2):63-77. PubMed ID: 30779598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
    Adam SS; McDuffie JR; Ortel TL; Williams JW
    Ann Intern Med; 2012 Dec; 157(11):796-807. PubMed ID: 22928173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
    Raskob G; Büller H; Prins M; Segers A; Shi M; Schwocho L; van Kranen R; Mercuri M;
    J Thromb Haemost; 2013 Jul; 11(7):1287-94. PubMed ID: 23574579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing Edoxaban's Role in Anticoagulation.
    Guirguis E; Brown D; Grace Y; Patel D; Henningfield S
    J Pharm Pract; 2016 Jun; 29(3):228-38. PubMed ID: 27169733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
    Comerota AJ; Ramacciotti E
    Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.